Feature Reviews on Bacteriophages

A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Bacteriophages".

Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 7224

Special Issue Editor


E-Mail Website
Guest Editor
Department of Medical Biomaterials Engineering, Kangwon National University, Chuncheon 24341, Gangwon, Republic of Korea
Interests: microbial pathogenesis; phage control; antibiotic resistance mechanism; food safety
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The emergence of antibiotic-resistant bacteria has been accelerated due to the misuse and overuse of antibiotics, which has become a public health threat. The treatment of infectious diseases caused by multidrug-resistant pathogens is a challenge due to the limited options and frequent failure of conventional antibiotic therapy. The global concern with antibiotic resistance has led to the discovery of antibiotic alternatives such as antimicrobial peptides, biocontrol agents, antimicrobial adjuvants, and bacteriophages. Among these, bacteriophages have received great attention and are considered a safe and promising alternative to control antibiotic-resistant bacteria due to their specific ability to target bacteria. However, phage resistance limits the use of phage therapy in clinical practice. The phage-resistance mechanisms include receptor alteration, superinfection exclusion, restriction modification, abortive infection, and CRISPR-Cas systems. This Special Issue aims to discuss the anti-phage mechanisms in association with the evolutionary trade-offs (collateral sensitivity) and trade-ups (collateral resistance) to design effective bacteriophage-based intervention strategies.

Prof. Dr. Juhee Ahn
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

20 pages, 844 KiB  
Review
Evolutionary Dynamics between Phages and Bacteria as a Possible Approach for Designing Effective Phage Therapies against Antibiotic-Resistant Bacteria
by Mahadi Hasan and Juhee Ahn
Antibiotics 2022, 11(7), 915; https://doi.org/10.3390/antibiotics11070915 - 07 Jul 2022
Cited by 21 | Viewed by 6772
Abstract
With the increasing global threat of antibiotic resistance, there is an urgent need to develop new effective therapies to tackle antibiotic-resistant bacterial infections. Bacteriophage therapy is considered as a possible alternative over antibiotics to treat antibiotic-resistant bacteria. However, bacteria can evolve resistance towards [...] Read more.
With the increasing global threat of antibiotic resistance, there is an urgent need to develop new effective therapies to tackle antibiotic-resistant bacterial infections. Bacteriophage therapy is considered as a possible alternative over antibiotics to treat antibiotic-resistant bacteria. However, bacteria can evolve resistance towards bacteriophages through antiphage defense mechanisms, which is a major limitation of phage therapy. The antiphage mechanisms target the phage life cycle, including adsorption, the injection of DNA, synthesis, the assembly of phage particles, and the release of progeny virions. The non-specific bacterial defense mechanisms include adsorption inhibition, superinfection exclusion, restriction-modification, and abortive infection systems. The antiphage defense mechanism includes a clustered regularly interspaced short palindromic repeats (CRISPR)–CRISPR-associated (Cas) system. At the same time, phages can execute a counterstrategy against antiphage defense mechanisms. However, the antibiotic susceptibility and antibiotic resistance in bacteriophage-resistant bacteria still remain unclear in terms of evolutionary trade-offs and trade-ups between phages and bacteria. Since phage resistance has been a major barrier in phage therapy, the trade-offs can be a possible approach to design effective bacteriophage-mediated intervention strategies. Specifically, the trade-offs between phage resistance and antibiotic resistance can be used as therapeutic models for promoting antibiotic susceptibility and reducing virulence traits, known as bacteriophage steering or evolutionary medicine. Therefore, this review highlights the synergistic application of bacteriophages and antibiotics in association with the pleiotropic trade-offs of bacteriophage resistance. Full article
(This article belongs to the Special Issue Feature Reviews on Bacteriophages)
Show Figures

Figure 1

Back to TopTop